Development of the anti-arthritic agent Therafectin has been halted following an FDA advisory committee review of the drug Jan. 27, Greenwich says Jan. 31. FDA rejected the Therafectin NDA in September; the Arthritis Advisory Committee ratified that decision at its Jan. 27 meeting ("The Pink Sheet" Jan. 31, T&G-9). Greenwich says it "has ceased substantially all of its efforts to secure U.S. marketing approval for Therafectin and will begin to pursue strategic partnerships and other business arrangements focused upon maximizing the value of the company's remaining assets." Greenwich has laid off 44 employees, or 65% of its work force. The company reports it will continue development of two other anti-arthritics, GW-80126 and GW-92527. The first Phase II trial of GW-80126 is expected to conclude this year
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth